IKS01 / Iksuda Therap - LARVOL DELTA

IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor &[alpha] expression (AACR-NCI-EORTC 2019) - "Clinical validation of this approach for solid tumors has been limited, with trastuzumab emtansine, which targets HER2+ breast cancer, being the only ADC approved for treatment of solid tumors to date. Other ADCs targeting solid tumor indications have shown promise, including mirvetuximab soravtansine (MR), an ADC directed at folate receptor α (FRA)...Conclusion The combination of a stable conjugation technology and a novel highly-potent DNA monoalkylator has led to the development of an ADC format that has shown target-dependent anti-tumor efficacy in a pre-clinical model of platinum-resistant ovarian cancer with low levels of FRA expression. These preclinical data suggest that IKS01 is a promising therapeutic candidate for the treatment of FRA-positive ovarian cancer, even when the level of surface expression of FRA is low."

IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression (ESMO 2019) - "Clinical evaluation of mirvetuximab soravtansine in solid tumor indications demonstrated that FRA can be successfully targeted by an ADC. IKS01 shows marked anti-tumor efficacy in pre-clinical models of ovarian and lung cancer, even in models with low or moderate FRA expression. Legal entity responsible for the study: Iksuda Therapeutics Ltd. Funding: Iksuda Therapeutics Ltd."

Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression (Businesswire) - “IKS01, an ADC targeting the folate receptor, has shown significant anti-tumour efficacy in pre-clinical models of ovarian and lung tumours…IKS01 is target specific and these new data confirm that it is highly effective in causing tumour regression in FRA-expressing models at doses that are well-tolerated, significantly more active than a benchmark ADC and caused complete regressions in low/moderate FRA-expressing models. The IKS01 data is a major advancement of Iksuda’s ADC drug pipeline, from which it aims to progress multiple candidates towards first clinical studies in 2020.”

New trial • Preclinical